In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators, CGEN- 15001T and CGEN-15022. Under the terms of the agreement, Bayer HealthCare and Compugen are jointly pursuing a preclinical research program. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. During 2014 Compugen reported the achievement of two preclinical milestones in its cancer immunotherapy collaboration with Bayer Healthcare. In 2015, Compugen reported the achievement of a third milestone under its immuno-oncology collaboration with Bayer. All three milestones relate to CGEN-15001T.
“At Bayer HealthCare, we are impressed with Compugen’s ability to identify novel immune checkpoints through the use of their predictive discovery infrastructure, and are pleased to collaborate with their professional scientific team on therapeutic antibody development in the field of immuno-oncology.”
Karl Ziegelbauer, Head of Global Therapeutic Research Groups at Bayer HealthCare